文献速递鼻科

生物制剂、过敏原免疫治疗及药物治疗中重度过敏性鼻炎的疗效与安全性:网络Meta分析

Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate-to-Severe Allergic Rhinitis: A Network Meta-Analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2026-01-26

该网络Meta分析纳入28项随机对照试验(13,312例参与者),比较生物制剂、过敏原免疫治疗(AIT)和关键药物治疗对中重度过敏性鼻炎的疗效与安全性。结果显示,抗IL-4Rα治疗在改善鼻部症状和生活质量方面排名最高,抗IgE治疗和AIT优于所有药物治疗;鼻内糖皮质激素联合鼻内抗组胺药在眼部症状控制中排名最高。所有治疗安全性良好,生物制剂和AIT未显著增加不良事件风险。

要点

  • 抗IL-4Rα治疗在改善鼻部症状和生活质量方面排名最高。
  • 抗IgE治疗和AIT在鼻部症状控制上优于所有药物治疗。
  • 鼻内糖皮质激素联合鼻内抗组胺药对眼部症状控制排名最高。

核心结论

  • 生物制剂尤其是抗IL-4Rα治疗是控制鼻部症状最有效的干预措施,优于AIT和药物治疗。
  • 所有治疗均表现出良好的安全性,生物制剂和AIT未显著增加不良事件风险。

研究设计与样本

  • 网络Meta分析,纳入28项随机对照试验,共13,312例中重度过敏性鼻炎参与者。
  • 评估生物制剂(抗IgE、抗IL-4Rα)、AIT(6个月时间范围内评估)和关键药物治疗(鼻内糖皮质激素单用或联合抗组胺药)。

主要发现

  • 在总鼻部症状评分(TNSS)方面,抗IL-4Rα治疗最有效,其次为抗IgE治疗和AIT,均优于所有药物治疗。
  • 鼻内糖皮质激素联合鼻内抗组胺药在眼部症状控制方面排名最高。
  • 抗IL-4Rα治疗在改善鼻结膜炎生活质量问卷(RQLQ)方面也最优。
  • 所有治疗均显示出良好的安全性特征,生物制剂和AIT与安慰剂相比未显著增加不良事件风险。

关键数值与推荐

  • 疗效通过TNSS、TOSS和RQLQ的变化评估,治疗层级使用累积排名曲线下面积(SUCRA)概率建立。

临床怎么用

  • 为临床医生选择中重度过敏性鼻炎治疗方案提供了数据驱动的分层框架,支持个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of moderate-to-severe allergic rhinitis (AR) is challenging given numerous advanced therapies. A comparative, evidence-based treatment hierarchy to guide the selection of biologics, allergen immunotherapy (AIT), and advanced pharmacotherapies is critically lacking due to a paucity of head-to-head trials. This network meta-analysis established a treatment hierarchy for moderate-to-severe AR by comparing the efficacy and safety of biologics, AIT, and key pharmacotherapies. METHODS: We analyzed 28 randomized controlled trials (13,312 participants), which evaluated the efficacy and safety of biologics (anti-IgE, anti-IL-4Rα therapies), AIT (evaluated within a 6-month time frame to ensure comparability), and key pharmacotherapies (intranasal corticosteroids alone or combined with antihistamines) for moderate-to-severe AR. Efficacy was assessed by changes in the Total Nasal Symptom Score (TNSS), the Total Ocular Symptom Score (TOSS), and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). A treatment hierarchy was established using surface under the cumulative ranking curve (SUCRA) probabilities. RESULTS: For the TNSS, anti-IL-4Rα therapy was most effective, followed by anti-IgE therapy and AIT, which surpassed all pharmacotherapies. The combination of intranasal corticosteroid and intranasal antihistamine ranked the highest for ocular symptoms. Anti-IL-4Rα therapy was also superior for improving the RQLQ. Overall, all treatments demonstrated a favorable safety profile. Biologics and AIT did not show a significant increase in adverse events risk compared to placebo. CONCLUSIONS: This network meta-analysis establishes the first comprehensive treatment hierarchy for moderate-to-severe AR. Our findings demonstrate that biologics, particularly anti-IL-4Rα therapy, are the most effective interventions for nasal symptom control, ranking superior to AIT and pharmacotherapies, thus providing a robust, data-driven framework to personalize patient care.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Fang D, Wang C, et al. Efficacy and Safety of Biologics, Allergen Immunotherapy, and Pharmacotherapies for Moderate-to-Severe Allergic Rhinitis: A Network Meta-Analysis. Int Forum Allergy Rhinol. 2026. PMID: 41587102. doi:10.1002/alr.70108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。